Cookies

Like most websites The Pathologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Diagnostics Oncology, Regulation and standards, Genetics and epigenetics, Omics

Buying the Hype

To most medical professionals, the questionable nature of consumer genetic testing seems self-evident. Unfortunately, that isn’t the case for members of the general public, who – without an advanced education in molecular biology or oncology – lack the ability to critically evaluate the marketing of those kinds of tests. It’s a major concern, then, that the Internet marketing of these services is unregulated; commercial testing companies can make whatever claims they choose, which leads to wide variation in how their services are presented to the public. As a result, many physicians are concerned about the challenge this variation poses both to them in lifting the veil of confusion for their patients, and to the patients themselves, who are trying to make the best possible decisions for their own care.

A new study from the Dana-Farber Cancer Institute (Boston, MA, USA) has determined that websites advertising personalized cancer testing offer genetic tests whose value in clinical guidance has not been shown (1). Stacy Gray, lead author on the report, says, “Over 85 percent of the websites that marketed tumor testing marketed at least one or more tests that really have not been proven to improve patients’ outcomes. That means that there are many different types of tests on the Internet – some of them helpful and some of them not yet known to be helpful.” Even the tests that have clinical value aren’t always presented correctly – most Internet copy emphasizes the purported benefits of the tests while downplaying their limitations (1). “Websites marketing personalized cancer medicine tests, services or clinical care were much more likely to endorse the benefits of personalized cancer care than the potential limitations. For example, important issues such as the possibility of test failure or the fact that providers and labs often face a lot of uncertainty as they try to interpret complex genomic data were infrequently mentioned.”

Marketing claims made by the websites include such statements as, “We want you to have the peace of mind that comes from knowing you are doing everything you can to maximize the success of your treatment and limit treatment side effects as much as possible,” or, “Why use your body to investigate a drug’s effectiveness, when we can garner the results safely and in a timely manner? (2)” Even more worryingly, some suggest making or modifying treatment plans developed by the patients’ care providers, saying, “If you want the peace of mind that comes from knowing that you are doing everything possible to beat your cancer with the least amount of side effects and the shortest recovery time possible, let [our company] prepare a [personalized plan] for you.“ Or even claiming, “Our team has helped patients become aware of, and gain rapid access to, innovative treatments that were not initially prescribed by their oncologists. (2)” It’s possible that these often unfounded claims may actually have a detrimental effect on patients’ care if they promote products or treatment pathways not recommended by doctors.

Gray feels that another major risk is patients having unrealistic expectations if they believe many of the online claims. “If patients see interesting information online,” she warns, “they should definitely ask their doctor about it. And given the disproportionate claims of benefit and promotion of tests that may not be beneficial, we would urge clinicians and patients to critically evaluate online personalized cancer products.”

Recently, the US Food and Drug Administration has stated its intention to begin regulating genomic testing more broadly – a promising step forward for a market whose information is as yet unsupervised by any such agency. But even if such regulation does materialize, as consumer genetic testing becomes more popular and more affordable, it will become increasingly important for medical professionals to assist patients in determining the best way forward for their own treatment.

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. Dana-Farber Cancer Institute, “Unregulated web marketing of genetic tests for personalized cancer care raises concerns in new study” (2015). Available at: bit.ly/1BOC0Eg. Accessed April 17, 2015.
  2. SW Gray, et al., “Marketing of personalized cancer care on the web: an analysis of Internet websites”, J Natl Cancer Inst, 107, djv030 (2015). PMID: 25745021.
About the Author
Michael Schubert

While obtaining degrees in biology from the University of Alberta and biochemistry from Penn State College of Medicine, I worked as a freelance science and medical writer. I was able to hone my skills in research, presentation and scientific writing by assembling grants and journal articles, speaking at international conferences, and consulting on topics ranging from medical education to comic book science. As much as I’ve enjoyed designing new bacteria and plausible superheroes, though, I’m more pleased than ever to be at Texere, using my writing and editing skills to create great content for a professional audience.

Related Application Notes
Superior Determination of HPV using RNAscope™ In Situ Hybridization

| Contributed by Bio-Techne

Biomarker Optimization on LabSat® Research

| Contributed by Lunaphore Technologies

Diagnostics Genetics and epigenetics
A single NGS workflow for comprehensive genomic profiling

| Contributed by QIAGEN

Related Product Profile
Diagnostics Genetics and epigenetics
QIAseq® Pan Cancer Multimodal cuts user interventions by 50%

| Contributed by QIAGEN

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register